Trump Signs Order to Boost Psychedelic Research for Mental Health Treatments

Want the full story?
Read the complete article at KVIA
AI Summary
President Donald Trump has signed a decree aimed at advancing research on psychedelic drugs, particularly ibogaine, to explore new treatments for mental health issues. The initiative includes a $50 million federal investment and aims to eliminate legal barriers for researchers studying these substances. Trump emphasized the potential of psychedelics to transform the lives of individuals suffering from severe mental illnesses, including veterans. Health officials expect that the approval process for these treatments could be expedited significantly, potentially within weeks. However, concerns have been raised about the safety and regulatory standards of such fast-tracked research.
Key Details: • Federal investment of $50 million allocated for psychedelic research. • Ibogaine is the primary psychedelic mentioned in the decree. • FDA may approve treatments in weeks instead of over a year. • Concerns exist regarding the safety and regulation of accelerated research.